Cross-Sector entity

Supernus Pharmaceuticals

Company SUPN
5.2

Of the tracked stories, 3 of 6 also mention Axon Enterprise, the most common co-covered peer. The 163-day window averages about 0.3 stories each week. The busiest single day carried 3. earnings accounts for 2 of the 6 tracked stories, while 3 other categories carry the remainder.

6 verified stories tracked

Last mentioned: Aug 4, 2026

RSS updates
Share

Entity pulse

Recent coverage · Supernus Pharmaceuticals

↑
6 stories
5.2 avg impact
17% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 17 percentage points.

  • 17% positive
  • 83% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Supernus Pharmaceuticals

Of the tracked stories, 3 of 6 also mention Axon Enterprise, the most common co-covered peer. The 163-day window averages about 0.3 stories each week. The busiest single day carried 3. earnings accounts for 2 of the 6 tracked stories, while 3 other categories carry the remainder. 0% of these stories carry negative sentiment. This profile follows 6 Cross-Sector stories mentioning Supernus Pharmaceuticals across the period from February 23, 2026 to August 4, 2026. The tracked stories average 4.5 original sources each.

Stories tracked
6
Per week
0.3
Negative
0%
Sources per story
4.5

Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Supernus Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Expected Deal Close

    The all-stock merger is anticipated to close, pending shareholder and regulatory approvals.

  2. Merger and Earnings Announcement

    Supernus unveils definitive agreement to merge with Indivior and releases Q2 2026 financial results.

Stories mentioning Supernus Pharmaceuticals 6

Healthcare acquisition Positive 6

Supernus–Indivior Merger Creates 11-Drug CNS Giant, $125M Synergy Target

Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.

4 sources

Source: The Motley Fool · Eric Volkman (us)

Finance earnings Neutral 5

Sector Divergence: Q4 2025 Earnings Reveal Resilience in MedTech and Retail

A wave of Q4 2025 earnings reports from mid-cap leaders across healthcare, automotive, and retail sectors highlights a bifurcated recovery. While MedTech and high-end retail show margin expansion, the EV and industrial sectors continue to navigate significant production and scaling headwinds.

7 sources
Finance earnings Neutral 5

Axon Enterprise Eyes Software Growth as Q4 Earnings Approach

Axon Enterprise is set to report Q4 2025 results, with investors focused on the adoption of AI-driven tools like Draft One and the continued rollout of TASER 10. Meanwhile, specialty pharma players Corcept and Supernus prepare to disclose their own year-end performance amid shifting regulatory and competitive landscapes.

3 sources
Biotech pharma Neutral 5

Pharma Earnings Preview: Supernus and Corcept Set for Q4 2025 Results

Supernus Pharmaceuticals and Corcept Therapeutics are preparing to report Q4 2025 results, with investors focusing on CNS product growth and cortisol-modulating pipeline progress. These reports will provide critical data on market penetration for key therapies like Qelbree and Korlym amidst a shifting regulatory landscape.

3 sources
Healthcare market trends Neutral 5

Q4 Earnings Preview: Axon, Supernus, and Corcept Set for Key Results

Investors are bracing for Q4 2025 results from Axon Enterprise, Supernus Pharmaceuticals, and Corcept Therapeutics, with Axon looking to maintain its perfect revenue beat streak. While Axon dominates the public safety tech space, the pharmaceutical players face varying expectations regarding clinical pipelines and market penetration for core therapies.

3 sources

Source: Seeking Alpha · Seeking Alpha